Documentation of published clinical trials and ... - Institut Hiscia

Survival Breast Cancer 5.2.3
Hoffmann J., Hajto T. (1982) Iscadorbehandlung beim metastasierenden Mamma-Karzinom.
[Iscador treatment of breast cancer with metastases.] Krebsgeschehen 14 (3), 71–75.
Study design
Design Retrospective study with 3 groups.
Patients 495 operated patients with breast cancer and metastases, from the Lukas
Klinik.
Treatment Group 1 (n = 116): Received Iscador for at least 3 months after operation,
and after diagnosis of metastases, 8 series of Iscador a year for at least one
year.
Group 2 (n = 138): Did not receive adequate Iscador until after diagnosis of
metastases (8 series a year for at least one year).
Group 3 (n = 241): Did not receive any adequate treatment with Iscador.
All patients of the groups became chemotherapy, radiotherapy and
hormone therapy to similar degrees.
Length of study 1963–1980.
Measurement Survival.
Most important results
Group 1 and group 2 achieved a median survival of 29 and 23.5 months respectively, in
comparison with 17 months in group 3. The differences from groups 1 and 2 to group 3 are
statistically significant (p = 0.001 and p = 0.03 respectively). When comparing the patients with
localised relapse, the median survival in the Iscador groups 1 and 2 (48.5 months) was
significantly higher than in group 3 (27.5 months), with p = 0.008.
© Verein für Krebsforschung, CH-4144 Arlesheim